Literature DB >> 568886

Sarcoidosis and its ophthalmic manifestations.

C D Obenauf, H E Shaw, C F Sydnor, G K Klintworth.   

Abstract

Of 532 cases of sarcoidosis in the southeastern United States, ocular manifestations were a prominent feature of the disease in 202 (38%) of the patients. Approximately one fifth of them sought medical attention because of ocular complaints. This was the second most frequent clinical manifestation, exceeded only by pulmonary symptoms. When ocular segment structures were affected, the anterior segment was involved in 171 (84.7%) of cases. Chronic granulomatous uveitis was the most common abnormality in 106 cases (52.5%). Posterior segment disease occurred in 51 (25.3%) of cases, usually in the form of chorioretinitis or preiphlebitis; it was sometimes the sole manifestation of ocular sarcoidosis, but usually accompanied abnormalities in the anterior part of the eye. The incidence of central nervous system sarcoidosis was increased when posterior segment involvement was observed. Orbital and adnexal structures, primarily lacrimal gland, were affected in 53 (27.7%) of cases.

Entities:  

Mesh:

Year:  1978        PMID: 568886     DOI: 10.1016/0002-9394(78)90184-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  81 in total

Review 1.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Cigarette smoking and male sex are independent and age concomitant risk factors for the development of ocular sarcoidosis in a New Orleans sarcoidosis population.

Authors:  Adam C Janot; Dörte Huscher; McCall Walker; Harmonjot K Grewal; Mary Yu; Matthew R Lammi; Lesley Ann Saketkoo
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2015-07-22       Impact factor: 0.670

3.  Ocular manifestations of Behçet's disease in Jordanian patients.

Authors:  Mohammed A Abu-Ameerh; Sawsan F Mohammed; Mona T Mohammad; Osama H Ababneh; Muawyah D Al-Bdour
Journal:  Saudi J Ophthalmol       Date:  2013-07-01

4.  Neurosarcoidosis: therapeutic success with methotrexate.

Authors:  F G Soriano; P Caramelli; R Nitrini; A S Rocha
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

5.  Reversible endocrine dysfunction and pituitary stalk enlargement.

Authors:  A Chico; M Puig-Domingo; P Martul; M De Juan; J M Prats; D Mauricio; S M Webb
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

6.  [Bilateral chorioretinitis with hilus lymphoma. Differential diagnosis and treatment].

Authors:  J Wrede; R Max; U Wiehler; M Becker
Journal:  Ophthalmologe       Date:  2008-10       Impact factor: 1.059

Review 7.  [Ocular sarcoidosis].

Authors:  C Springer-Wanner; T Brauns
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

Review 8.  Ocular myositis.

Authors:  Clare L Fraser; Simon E Skalicky; Avinash Gurbaxani; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

9.  When should sarcoidosis be treated?

Authors:  R C Young; R E Rachal; C L Cowan
Journal:  J Natl Med Assoc       Date:  1986-09       Impact factor: 1.798

10.  Solitary choroidal mass as the presenting sign in systemic sarcoidosis.

Authors:  R J Olk; M J Lipmann; H C Cundiff; J Daniels
Journal:  Br J Ophthalmol       Date:  1983-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.